Pura Vida Investments’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Pura Vida Investments’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,350	Closed	-$486K	–	117
2018 Q3	$486K	Buy	1,350 +17	+1%	+$5.82K	0.1%	102
2018 Q2	$488K	Buy	+1,333	New	+$475K	0.2%	82
2015 Q2	–	Sell	-75	Closed	-$636K	–	84
2015 Q1	$636K	Hold	75	–	–	0.33%	53
2014 Q4	$656K	Buy	+75	New	+$435K	0.24%	65

Other funds holding EIGR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pura Vida Investments's EIGR Position: Q4 2018 in Review

Pura Vida Investments sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2018, closing a stake of 1,350 shares — an estimated $486K sold.

Pura Vida Investments first reported a position in EIGR in Q4 2014 and held it in 4 quarters. The position peaked at $656K in Q4 2014. 68 funds tracked by Wall St. Rank hold EIGR as of Q4 2018.

Pura Vida Investments reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Pura Vida Investments sold 1,350 Eiger BioPharmaceuticals, Inc. shares in Q4 2018, an estimated $486K.
Pura Vida Investments first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
Pura Vida Investments's Eiger BioPharmaceuticals, Inc. position peaked at $656K in Q4 2014.
68 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2018.

Based on Pura Vida Investments's 13F filing for Q4 2018, filed 14 Feb 2019.